Compare iShares MSCI Canada (TSX) (EWC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI Canada (TSX) trades at $58.84 (market cap $6.99B), while Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B). The key difference: iShares MSCI Canada (TSX) is far larger — about 3.3× Recursion Pharmaceuticals Inc's market cap, and iShares MSCI Canada (TSX) is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Canada (TSX) for 57 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EWC | RXRX | |
|---|---|---|
Market Cap | $6.99B | $2.14B |
Volume | 1,625,847 | 30,789,535 |
Sector | Broad Market / Factor | Health |
52-Week High | $62.64 | $6.79 |
52-Week Low | $49.72 | $2.84 |
Typical Hold Time | 57 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $57.94, down 2.1% today amid a bearish technical signal with moving averages indicating selling pressure. The stock lacks disclosed financial ratios, limiting fundamental clarity. Recent news highlights trade tensions between the U.S. and Canada, with potential impacts on cross-border economic activity and market sentiment.
The outlook is clouded by geopolitical risks from U.S.-Canada trade disputes, which could pressure performance. Investment opportunities hinge on resolution of trade frictions and improved economic data. Key risks include prolonged trade uncertainty and volatility from political developments.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
